Mahesh Krishnan insider trades: Halozyme Therapeutics (HALO) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Mahesh reports to the SEC
Open-market buys and sales
2 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jun 29, 2026 | HALO | ↓ Sell | 7,304 | $75.00 | $548K | Direct | Jun 30, 2026 (1d) |
| Apr 4, 2023 | KDNY | ↓ Sell | 924 | $23.01 | $21K | Direct | Apr 4, 2023 (0d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other HALO insiders
Open-market trades in the last 12 months
About Mahesh Krishnan's insider trades
Mahesh Krishnan is a director at Halozyme Therapeutics (HALO). Since Apr 4, 2023, Mahesh has reported no open-market purchases and 2 sales worth $569K on SEC Form 4. In the last 12 months: 1 sale ($548K).
Their filings also include grants and awards (4 filings), option exercises (2 filings), shares returned to the company (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every HALO insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.